RedHill Sells Talicia to Apotex for $18M Upfront, Unlocking Cash for Growth
RDHL is trading near its 52-week low of $0.57 (11% above the low) on light trading volume (0.2× avg).
Summary
RedHill is divesting Talicia, its H. pylori treatment, to Apotex for $18 million in upfront cash plus milestone payments. The deal includes an additional $35 million in potential payments based on worldwide net sales milestones. Apotex will receive RedHill's 70% interest in Talicia, following Apotex's prior acquisition of Cumberland Pharmaceuticals' U.S. branded business. The divestiture provides immediate liquidity to RedHill, which has been raising capital through dilutive private placements and ATM offerings amid going concern warnings. This follows financing moves in June and July, including a $6 million upfront private placement and ATM expansions. The divestiture shifts focus toward strategic growth opportunities, likely its pipeline assets like opaganib.
At the time of this announcement, RDHL was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $0.57 to $2.79. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.